TLDR
- AbbVie delivered Q1 adjusted earnings of $2.65 per share, surpassing the consensus estimate of $2.59
- Quarterly revenue reached $15 billion, representing a 12% year-over-year increase and exceeding the $14.72 billion projection
- The immunology division expanded 16%, while neuroscience surged 26% during the period
- The company elevated its full-year 2026 adjusted EPS forecast to $14.08–$14.28, up from the previous $13.96–$14.16 range
- ABBV shares advanced 2.5% in premarket activity, clawing back a portion of the stock’s 13% year-to-date loss
Heading into Wednesday’s quarterly report, AbbVie shares had tumbled 13% year-to-date. The pharmaceutical company’s latest results gave investors reason for renewed optimism.
The biopharmaceutical firm posted first-quarter adjusted earnings of $2.65 per share, climbing from $2.46 in the comparable period last year and exceeding the Street’s $2.59 projection. Quarterly revenue totaled $15 billion, marking a 12% year-over-year advance and beating analyst expectations of $14.72 billion.
ABBV shares climbed 2.5% to $202.63 in premarket session following the announcement.
The revenue outperformance was primarily fueled by strength across two critical therapeutic segments. The immunology division generated 16% growth, while the neuroscience business delivered an even more robust 26% expansion.
Skyrizi and Rinvoq remained the cornerstone performers within the immunology portfolio. Skyrizi, indicated for treating arthritis and Crohn’s disease, posted 31% revenue growth during the quarter. Rinvoq contributed with 23% advancement.
These gains successfully offset a 39% revenue decline from Humira. The former blockbuster medication faces intensifying competition from biosimilar alternatives, and its role within the overall product mix continues to diminish.
Guidance Gets a Lift
AbbVie increased its full-year 2026 adjusted EPS projection to a range of $14.08 to $14.28, elevated from the previous guidance of $13.96 to $14.16. The current Wall Street consensus stands at $14.12, positioning the midpoint of the updated range modestly above analyst expectations.
The upward revision to guidance reflects management’s growing confidence in sustained performance from its immunology and neuroscience product portfolios.
On a GAAP basis, the company reported net income of $695 million, or $0.39 per share, for the quarter. This compares to $1.29 billion, or $0.72 per share, during the same quarter last year. The year-over-year GAAP decline incorporates expenses excluded from adjusted metrics.
The Bigger Picture for ABBV
Shares had faced headwinds entering this earnings event, down 13% for the year through Tuesday’s market close.
The 2.5% premarket rally indicates investors responded favorably to both the earnings beat and enhanced guidance, although significant ground remains to be recovered.
Skyrizi and Rinvoq have unquestionably emerged as the primary growth drivers for AbbVie’s business, with their collective performance successfully compensating for Humira’s persistent decline.
The neuroscience division is establishing itself as an increasingly important revenue contributor. The segment’s 26% expansion rate demonstrates meaningful progress beyond the company’s traditional immunology strength.
AbbVie’s adjusted earnings of $2.65 per share represented the second straight quarter of year-over-year improvement on this measure, leaving the prior-year result of $2.46 firmly behind.
The pharmaceutical company’s elevated guidance range of $14.08 to $14.28 in adjusted earnings per share establishes the new full-year benchmark that investors and Wall Street will monitor throughout the remainder of 2026.
